Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluating the response ratio of an ionization chamber filled with air to that with P-10 gas for <sup>41</sup>Ar calibration.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2025

Same author

Loss of Ftsj1 perturbs codon-specific translation efficiency in the brain and is associated with X-linked intellectual disability.

Science advances·2021

Same author

Corrigendum to "Antithrombotic therapy trends in non-valvular atrial fibrillation patients undergoing percutaneous coronary stent implantation: Results from a survey among fellows at the Japanese College of Cardiology" [J. Cardiol. 72 (2) (2018) 113-119].

Journal of cardiology·2018

Same author

Long-term clinical impact of serum albumin in coronary artery disease patients with preserved renal function.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2018

Same author

Selective intracellular vaporisation of antibody-conjugated phase-change nano-droplets in vitro.

Scientific reports·2017

Same author

Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis.

Mucosal immunology·2014

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Protein transduction by pseudotyped lentivirus-like nanoparticles.

T Aoki¹, K Miyauchi, E Urano

¹AIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.

|April 1, 2011

Summary

Researchers developed a novel lentivirus-like nanoparticle (LENA) for efficient protein transduction into mammalian cells. This method delivers thousands of protein molecules without damaging cellular DNA, offering potential for various applications.

More Related Videos

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

Related Experiment Videos

Last Updated: Jun 3, 2026

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

Area of Science:

Biotechnology
Molecular Biology
Cell Biology

Background:

Establishing efficient and reproducible methods for protein transduction into mammalian cells remains a challenge.
Current methods may require highly purified proteins or can damage cellular DNA.

Purpose of the Study:

To develop a novel, simple, efficient, and reproducible method for protein transduction into mammalian cells.
To demonstrate the feasibility of using lentivirus-like nanoparticles (LENAs) for protein delivery.

Main Methods:

Development of a lentiviral vector system to package foreign proteins into lentivirus-like nanoparticles (LENAs).
Fusion of a reporter protein, beta-lactamase (BlaM), to Gag for incorporation into LENAs.
Production of BlaM-containing LENAs via co-transfection with VSV-G pseudotyping.
Transduction of mammalian cells (293T and MT-4) with BlaM-loaded LENAs and detection of BlaM activity.

Main Results:

Successfully produced LENAs containing thousands of beta-lactamase (BlaM) enzyme molecules per capsid.
Demonstrated efficient transduction of BlaM into the cytoplasm of mammalian cells via LENA infection.
Confirmed BlaM activity through cleavage of a fluorescent substrate (CCF2-AM).
Showed that LENA-mediated protein transduction does not damage cellular DNA.

Conclusions:

LENA technology provides a novel and effective method for transient protein transduction in mammalian cells.
This approach bypasses the need for highly purified proteins and avoids cellular DNA damage.
LENA-mediated protein delivery holds significant potential for diverse basic research and clinical applications.